Changes

no edit summary
Line 33: Line 33:  
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
 
|-
 
|-
|Chronic neutrophilic leukaemia||Disease||Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally|| || || || ||FQR|| ||
+
|Chronic neutrophilic leukaemia||Disease|| || || || || ||FQR|| ||
|
+
|Chronic Neutrophilic Leukemia (CNL)
|
+
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
 
|-
 
|-
|Chronic eosinophilic leukaemia||Disease||Chelsea D. Kramish; Daynna J.Wolff  Pending Review*|| || || || ||FQR|| ||
+
|Chronic eosinophilic leukaemia||Disease|| || || || || ||FQR|| ||
|
+
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|
+
|Chelsea D. Kramish; Daynna J.Wolff
 
|-
 
|-
|Polycythaemia vera||Disease||Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center|| || || || ||FQR|| ||
+
|Polycythaemia vera||Disease|| || || || || ||FQR|| ||
|
+
|Polycythemia Vera (PV)
|
+
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
 
|-
 
|-
 
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| ||
 
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| ||
|
+
|Essential Thrombocythemia (ET)
 
|
 
|
 
|-
 
|-